ML24221A145: Difference between revisions
StriderTol (talk | contribs) (StriderTol Bot insert) |
StriderTol (talk | contribs) (StriderTol Bot change) |
||
Line 22: | Line 22: | ||
Subcommittee Review and Comments on Financial Assurance Requirements for Disposition of Category 1-3 Byproduct Material Radioactive Sealed Sources | Subcommittee Review and Comments on Financial Assurance Requirements for Disposition of Category 1-3 Byproduct Material Radioactive Sealed Sources | ||
Submitted: | Submitted: August 8th, 2024 | ||
Subcommittee Membership Richard L. Green, BS Pharm (Chair) | Subcommittee Membership Richard L. Green, BS Pharm (Chair) | ||
Line 30: | Line 30: | ||
Richard Harvey, DrPH Zoubir Ouhib, MS | Richard Harvey, DrPH Zoubir Ouhib, MS | ||
Harvey B. Wolkov, MD NRC Staff Resource: | Harvey B. Wolkov, MD NRC Staff Resource: Daniel Shaw | ||
Charge | Charge | ||
Line 50: | Line 50: | ||
: 4. A table of examples would be helpful to licensees and regulators. | : 4. A table of examples would be helpful to licensees and regulators. | ||
Specific Comments on the | Specific Comments on the Regulatory Basis Document : | ||
: 1. A definition should be provided for a self shielded irradiator | : 1. A definition should be provided for a self shielded irradiator | ||
Respectfully submitted on August 8th, 2024, Subcommittee on Financial Assurance Requirements for Disposition of Category 1-3 Byproduct Material Radioactive Sealed Sources Advisory Committee on the Medical Uses of Isotopes (ACMUI) | Respectfully submitted on August 8th, 2024, Subcommittee on Financial Assurance Requirements for Disposition of Category 1-3 Byproduct Material Radioactive Sealed Sources Advisory Committee on the Medical Uses of Isotopes (ACMUI) | ||
U.S. Nuclear Regulatory Commission (NRC)}} | U.S. Nuclear Regulatory Commission (NRC)}} |
Latest revision as of 10:35, 4 October 2024
ML24221A145 | |
Person / Time | |
---|---|
Issue date: | 08/08/2024 |
From: | Advisory Committee on the Medical Uses of Isotopes, Office of Nuclear Material Safety and Safeguards |
To: | |
References | |
Download: ML24221A145 (1) | |
Text
U.S. Nuclear Regulatory Commission (NRC)
Advisory Committee on the Medical Uses of Isotopes (ACMUI)
Draft Report
Subcommittee Review and Comments on Financial Assurance Requirements for Disposition of Category 1-3 Byproduct Material Radioactive Sealed Sources
Submitted: August 8th, 2024
Subcommittee Membership Richard L. Green, BS Pharm (Chair)
Rebecca Allen, MS
Richard Harvey, DrPH Zoubir Ouhib, MS
Harvey B. Wolkov, MD NRC Staff Resource: Daniel Shaw
Charge
On April 8, 2024, the ACMUI Chair created a subcommittee to update the regulations in 10 CFR 30.35 that deal with financial assurance for Category 1 and Category 2 material. The Financial Assurance Requirements for Disposition of Category 1-3 Byproduct Material Radioactive Sealed Sources subcommittees charge is to review and comment on the NRC staffs regulatory basis document. A joint NRC / Agreement State working group has drafted this document in accordance with Commission Direction.
=
Background===
The U.S. Nuclear Regulatory Commission (NRC) is considering revising the requirements in Title 10 of the Code of Federal Regulations (10 CFR) 30.35, Financial Assurance and Recordkeeping for Decommissioning. The rulemaking would establish new decommissioning financial assurance (DFA) requirements for the disposition of Category 1-3 byproduct material radioactive sealed sources (RSSs).
The NRCs regulations in 10 CFR 30.35 require a fixed dollar amount of financial assurance or a decommissioning funding plan (DFP) for licensees possessing byproduct material with a half-life greater than 120 days and at activity levels above certain thresholds. However, the thresholds for sealed byproduct material are such that many licensees possessing Category 1-3 byproduct material RSSs are not required to provide financial assurance for decommissioning.
The Commission approved initiation of this rulemaking in Staff Requirements Memorandum (SRM) SECY-16-0115, Staff Requirements - SECY-16-0115Rulemaking Plan on Financial Assurance for Disposition of Category 1 and 2 Byproduct Material Radioactive Sealed Sources, dated December 8, 2021. The next step in the NRCs rulemaking process is the development of a regulatory basis that serves as a precursor to the proposed rule. This regulatory basis document summarizes the current regulatory framework, describes the regulatory issues, and evaluates alternatives for establishing financial assurance requirements. This regulatory basis also includes a cost benefit analysis that considers impacts to the NRC, Agreement States, and industry (i.e., licensees) for each alternative.
General Comments:
- 1. The general opinion of the subcommittee members was that the regulatory basis document was well developed, and effectively outlined the regulatory alternatives.
- 2. The subcommittee supports the recommendation that the agency conduct rulemaking as described in Alternative 6b of this regulatory basis.
- 3. A historical review of how financial assurance requirements have changed prior to the current regulations in place.
- 4. A table of examples would be helpful to licensees and regulators.
Specific Comments on the Regulatory Basis Document :
- 1. A definition should be provided for a self shielded irradiator
Respectfully submitted on August 8th, 2024, Subcommittee on Financial Assurance Requirements for Disposition of Category 1-3 Byproduct Material Radioactive Sealed Sources Advisory Committee on the Medical Uses of Isotopes (ACMUI)
U.S. Nuclear Regulatory Commission (NRC)